Kornimate/medical-research-clean huggingface dataset:
a trial of neoadjuvant chemotherapy for stage ii, iii esophageal squamous cell carcinoma

Conditions: Stage II and III Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to determine whether docetaxel, cisplatin, and capecitabine (dcx) are effective as the neoadjuvant chemotherapy before esophagectomy in patients with loco-regional esophageal squamous cell carcinoma (escc).


Eligibility criteria:
inclusion criteria: 1. histologic diagnosis of squamous cell thoracic esophageal carcinoma of stage ii or iii, which is potentially resectable. 2. patients must not have received any prior anticancer therapy. 3. more than 6 months of expected survival. 4. age ranges from 18 to 70 years. 5. absolute white blood cells count ≥4.0×109/l, neutrophil ≥1.5×109/l, platelets ≥100.0×109/l, hemoglobin ≥90g/l, and normal functions of liver and kidney. 6. karnofsky performance status (kps) of 90 or more. 7. signed informed consent document on file. exclusion criteria: 1. patients are diagnosed or suspected to be allergic to docetaxol or cisplatin or capecitabine. 2. patients with concomitant hemorrhagic disease. 3. pregnant or breast feeding. 4. inability to use gastric conduit after esophagectomy because of a prior surgery. 5. patients with concomitant peripheral neuropathy, whose common toxicity criterion (ctc) status is 2 or even more. 6. have a prior malignancy other than esophageal carcinoma, carcinoma in situ of the cervix, nonmelanoma skin cancer or cured early stage of prostate cancer.
a study of the effect of glucagon-like peptide 1(glp-1) receptor agonist in combination with metformin therapy on diabetes remission in subjects with newly diagnosed type 2 diabetes who are overweight or obese

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine the effect of glp-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese

most of type 2 diabetes are characterized by being overweight or obese mainly caused by insulin resistance. glp-1 receptor agonist has been proved to help to lose weight and improve insulin resistance. in this study, we suppose that glp-1 receptor agonist has the effect of inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese and has its advantages

Eligibility criteria:
inclusion criteria: * a signed and dated informed consent form obtained from the subject before any study related procedures take place. * age ≥18 years to ≤65 years at visit 1. * the subject has a new diagnosis of type 2 diabetes without any treatment. * hba1c ≥8.0% to ≤14.0% at visit 1. * bmi(body mass index)≥24kg/m2 to ≤40kg/m2 at visit 1. exclusion criteria: * the subject has a history of type 1 diabetes or a secondary form of diabetes. * the subject has received an anti-diabetic drug before the screening visit. * treatment with systemic steroids 2 months prior to screening * treatment with anti-obesity drug 2 months prior to screening or any other treatment at the time of screening(i.e. surgery etc) leading to unstable body weight. * the subject has a history of acute or chronic pancreatitis * any gastrointestinal diseases or surgeries that induce chronic malabsorption * cancer and medical history of cancer(except basal cell skin cancer or squamous cell skin cancer). * the subject has a history of recurrent severe hypoglycaemia. * cardiovascular disease,within the last 6months prior to screening,defined as: stroke;decompensated heart failure new york heart association(nyha) class iii or iv;myocardial infarction;unstable angina pectoris;or coronary bypass graft or angioplasty. * uncontrolled treated/untreated severe hypertension (systolic blood pressure ≥180 millimetre(mm) mercury(hg) and/or diastolic blood pressure ≥100 millimetre(mm) mercury(hg). * impaired liver function,defined as alanine aminotransferase(alt) or aspartate aminotransferase(ast) ≥2.5 times upper limit of normal. * impaired renal function,defined as serum-creatinine ≥125umol/l for males and ≥110umol/l for females. * females who are pregnant or breast-feeding, males and females of childbearing potential,who do not agree to prevent conception during the study. * known or suspected abuse of alcohol,narcotics or illicit drugs.
quality of life, treatment experience and cost of treatment with somatostatin analogues in patients with gastroenteropancreatic neuroendocrine tumours

Conditions: Gastroenteropancreatic Neuroendocrine Tumours

Summary: data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (ssa) treatment related costs in clinical practice in the nordic countries. such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.


Eligibility criteria:
inclusion criteria: * signed informed consent * diagnosed with a gastroenteropancreatic neuroendocrine tumour (gep-net) and treated with ssa for at least three months but not more than 3 years * gep-net proliferation index ki 67 \<10% * over 18 years of age exclusion criteria: * no specific exclusion criteria defined
a study of selinexor in combination with azacitidine and venetoclax (sav regimen) in treatment naïve participants with acute myeloid leukemia

Conditions: AML, Adult

Summary: this is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.

this is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia. selinexor will be given orally at 60mg, d3,10,17 azacitidine will be given at 75mg/m2, d1-3, 8-9, 15-16 venetoclax will be given orally at 100mg on day 1 and 200mg on day 2, 400mg on day 3-14 28 days per cycle, patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive treatment until disease progression or unacceptable toxic effects.

Eligibility criteria:
inclusion criteria: * known and written informed consent voluntarily * age ≥ 18 years * newly diagnosed aml patients (per who 2022 classification criteria for aml diagnosis), who are not suitable for intensive chemotherapy: * ≥75 years or * aged 18 to 74 years with at least one of the following comorbidities: eastern cooperative oncology group (ecog) performance status score of 2 or 3 or 4; cardiac history of congestive heart failure (chf) requiring treatment or ejection fraction \ = 30 ml/min to \ 1.5 to \<= 3.0 × upper limit of normal (uln); any other comorbidity that the physician judges to be incompatible with intensive chemotherapy . * patients who are suitable for intensive chemotherapy but refuse it * liver function meets the following criteria: aspartate aminotransferase (ast) ≤ 3.0×uln\*; alanine aminotransferase (alt) ≤ 3.0×uln\*; bilirubin≤1.5×uln\*; for subjects \<75 years old, the bilirubin level can be ≤3.0×uln; * unless due to leukemic organ involvement. * renal function meets the following criteria: creatinine clearance ≥ 30 ml/min (cockroft-gault formula) * life expectancy ≥ 4 weeks exclusion criteria: * history of any malignancies prior to study entry with exception noted in the protocol. * participant has known hiv infection, active hepatitis b virus (hbv) and/or hepatitis c virus (hcv) . * participant has known active central nervous system (cns) involvement with aml. * must not have received prior anti-aml treatment except for hydroxyurea

Keywords: selinexor untreated aml azacitidine venetoclax
the scandinavian displaced lateral clavicle trial

Conditions: Clavicle Fracture

Summary: a multicentre multinational rct to investigate whether non-surgical treatment is non-inferior to surgical treatment for displaced extraarticular lateral clavicle fractures in adults.

the aim of this study is to investigate whether non-surgical treatment is non inferior to surgical treatment for displaced lateral clavicle fractures with regards to functional outcome measured with different patient-reported outcome measures. patients aged 18-65 years will be randomized to non-surgical or surgical (pragmatic) treatment. the primary outcome is the disabilities of arm hand and shoulder (dash) score at 1 year.

Eligibility criteria:
inclusion criteria: - displaced extraarticular lateral clavicle fracture (type ii or v according to the modified neer classification) exclusion criteria: * pathological fracture * open fracture * neurovascular injury * same-time fracture in the upper extremity * polytrauma * contraindications to surgery and/or anesthesia * unable to give informed consent * inability to complete follow-up

Keywords: displaced lateral clavicle fracture non-surgical surgical proms health economy non-inferior complications
the contemporary role of beta blockers in patients with acute myocardial infarction

Conditions: Acute Coronary Syndrome

Summary: the use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.in contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has been questioned, particularly in patients without reduced heart failure/ejection fraction after acute myocardial infarction.


Eligibility criteria:
inclusion criteria: * the diagnosis of acute myocardial infarction was clear and the left ventricular ejection fraction was normal exclusion criteria: * history of heart failure died in hospital

Keywords: left ventricular ejection fraction acute myocardial infarction beta-blocker
tofacitinib in early active axial spondyloarthritis:

Conditions: Axial Spondyloarthritis

Summary: this is a phase iv, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an nsaid) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axspa and inadequate response to at least one nsaid, with objective signs of inflammation.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of axspa and fulfilment of the asas classification criteria * symptom (back pain) duration for ≤ 2 years, according to the definition of early axial spa by asas. * active disease activity as defined by: basdai ≥4 and back pain score (basdai question 2) of ≥4 and objective signs of inflammation evident by osteitis in mri of sij and/or elevated serum crp levels. exclusion criteria: * active current infection, severe infections in the last 3 months * history of recurrent herpes zoster or disseminated herpes simplex * immunodeficiency * chronic hepatitis b, c or hiv infection * women: pregnant or lactating (have to practice reliable method of contraception) * other severe diseases conflicting with a clinical study, contraindications for mri
effect of red beetroot juice intake in adults with long covid-19

Conditions: Long COVID

Summary: red beetroot juice may have positive effects on multiple pathways involved in long covid. the aim of this pilot study was to explore the impact of beetroot juice supplementation on physical function, gut microbiota, and systemic inflammation in adults with long-covid

a single-center, double-blind, placebo-controlled randomized trial to test the effects of 14 days of beetroot juice supplementation on functional and biological outcomes in adults with long-covid. participants were randomized 1:1 to receive either daily oral supplementation with 200 ml beetroot juice or placebo for 14 days. the primary endpoint was the change from baseline to day 14 in the fatigue resistance test. secondary outcomes included the distance walked on the 6-min walk test, handgrip strength, and flow-mediated dilation. secondary endpoints also included changes from baseline in circulating inflammatory mediators, metagenomic and fecal water metabolomic profiles. partial least squares discriminant analysis (pls-da) models were built to evaluate the differences in biological variables associated with the interventions.

Eligibility criteria:
inclusion criteria: * a certification of a previous sars-cov-2 infection * a negative covid-19 swab test at least four weeks prior to the screening visit * meet the criteria for long-covid diagnosis according to the world health organization criteria * report persistent fatigue exclusion criteria: * intolerance to beetroot juice or its derivatives * clinical conditions and/or use of medications that may interfere with trial outcomes (e.g., pregnancy or breastfeeding, diabetes, use of steroids or non-steroidal anti-inflammatory drugs, immunosuppressants, nitrates) * participation in other intervention trials for long-covid
cranberry on urinary tract infections

Conditions: Urinary Tract Infection

Summary: this study aims to determine whether a cranberry concentrate reduces recurrent urinary tract infections (utis) in women who consume it. about 150 adult women will participate in this study. subjects will be randomized (like flipping a coin) to take either cranberry capsule or a placebo for 12 months. we expect cranberry supplement to have better results than the placebo. subjects will not know which supplement they are taking. the primary outcome is the number of utis over 12 months.

participants will attend their first study visit at a clinic at ubc. they will be randomized to the cranberry capsule or placebo. participants will be instructed to consume the assigned supplement for the next 12 months. a calendar will be provided to record compliance and recurrent uti. participants will also record any side effects. they will be phoned each month to encourage participation and adherence. at 8 weeks and 6 months, they will be asked to return to the clinic to complete a midline questionnaire which will ask about any recurrent utis experienced. more supplements will be provided at their 6-month visit. at 12 months, participants will return to the clinic to complete an endline questionnaire. they will return any leftover supplements, calendar and side effect diary. if participants withdraw from the study, they will still be encouraged to return at 12 months to complete the survey to allow for intent-to-treat analysis.

Eligibility criteria:
inclusion criteria: * females who have had at least 2 clinical-diagnosed symptomatic utis in the year preceding * are sexually active exclusion criteria: * current uti * pregnant or breastfeeding or planning a pregnancy in the next 12 months * a known allergy or intolerance to cranberry-containing products * a history of renal stones and/or renal transplantation * any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes * current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement * intermittent or indwelling catheterization * any anatomic abnormalities of the urinary tract * the use of any antibiotics within 2 weeks before study entry * the use of any natural health products, including herbs, homeopathic products, or other forms of cranberry supplements within 2 weeks before study entry
clinical efficacy of midodrine in symptomatic orthostatic hypotension

Conditions: Symptomatic Orthostatic Hypotension

Summary: to study the effect of midodrine against the symptoms of orthostatic hypotension

the efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. the study will involve approximately 9 overnight stays.

Eligibility criteria:
inclusion criteria: 1. male and female subjects must be 18 years of age or older and ambulatory. 2. females of child-bearing potential (focp) must have a negative serum beta human chorionic gonadotropin (hcg) pregnancy test. 3. a documented history of severe symptomatic orthostatic hypotension (soh) that, in the judgment of the treating physician, has required treatment with midodrine hcl, and has been at a stable dose for at least 3 months. 4. the subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (oh): dizziness, lightheadedness, feeling faint, or feeling like they might black out. exclusion criteria 1. the subject is a pregnant or lactating female. 2. the subject has pre-existing sustained supine hypertension greater than 180mmhg systolic and 110mmhg diastolic bp or had these measurements at the screening visit. sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes. 3. subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the medical monitor or study physician and documented prior to enrolling the subject. if agreement is reached between the investigator and sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study. 4. the principal investigator deems any clinical laboratory test (at the screening visit) abnormality to be clinically significant 5. the subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than study spd426-406). 6. current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures. 7. the subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram \[ecg\] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject. 8. known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients. 9. prior enrollment failure or randomization in this study. 10. history of alcohol abuse or other substance abuse within the last year.
the effects of auditory cues on gait mechanics in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to determine how using auditory cues of a metronome and music at various frequencies impacts the gait mechanics in people with parkinson's disease when walking over ground and on a treadmill. the investigators will enroll a total of 40 participants: 30 subjects with a diagnosis of parkinson's disease (10 in stage 1, 10 in stage 2, and 10 in stage 3) and 10 unimpaired subjects. participants will complete 7 different treadmill walking conditions and overground walking conditions while the investigators measure step length, cadence, gait speed, and variability of movement.


Eligibility criteria:
10 unimpaired controls and 30 subjects with parkinson's disease (described in detail below - see inclusion/exclusion criteria). the 30 subjects with parkinson's disease will be assigned into 3 groups (10 with h\&y stage 1, 10 with h\&y stage 2, and 10 with h\&y stage 3). inclusion criteria: * individuals with a diagnosis of parkinson's disease (made by movement disorders specialist) will be included in this study. additional inclusion criteria include: self-reported ability to walk \>10 m overground as well as walk on a treadmill for a total of 14 minutes with rest breaks as needed, and be classified as stage 1, 2, or 3 on the hoehn and yahr scale since these stages have the most independence with mobility (goetz et. al, 2004). exclusion criteria: * exclusion criteria include hoehn and yahr stage 4 and 5, uncontrolled cardiorespiratory/metabolic disease (e.g., cardiac arrhythmia, uncontrolled hypertension or diabetes, orthostatic hypertension, chronic emphysema), or other neurological or orthopedic disorders that may affect walking. the investigators will also exclude participants with severe communication impairments, which could impede understanding of the purpose or procedures of the study or an inability to comply with experimental procedures.
vibration training for preventing falls in healthy population and multiple sclerosis

Conditions: Falls Prevention

Summary: this study is to investigate the effects of controlled whole-body vibration training on reducing the likelihood of falls among healthy population and people with multiple sclerosis. (note: research not covered by sponsored funding)

for each population, the participants will be randomized into two groups.

Eligibility criteria:
inclusion criteria: for healthy population: * aged between 18 and 75 * no known history of musculoskeletal, neurological, cardiovascular, or pulmonary impairment for people with multiple sclerosis * self-reported multiple sclerosis and confirmed by the physician * no significant relapse within the past 8 weeks * to be able to walk independently a length of 25 feet * score on patient determined disease step \< 7 exclusion criteria: * subjects use any sedative of any type. * the heel bone density is less than -2.0
furosemide use to fill the bladder of pediatric females awaiting pelvic ultrasound

Conditions: Ovarian Torsion

Summary: the purpose of this study is to investigate whether or not furosemide causes the bladder to fill faster than iv fluids alone so that a pelvic ultrasound exam can be performed.

trans-abdominal pelvic ultrasound is the standard imaging modality for diagnosis of ovarian torsion in the pediatric population, however this requires that the patient have a full bladder at the time of imaging. this study will investigate whether low dose furosemide in addition to iv fluid boluses may provide a fast, effective, and non-invasive means to fill the bladder of pediatric females awaiting pelvic us. the target population are females age 8 to 18 years seen in the emergency room at connecticut children's medical center who are undergoing a trans-abdominal pelvic ultrasound to assess for ovarian torsion. enrolled patients will be randomized to the control (ivf bolus only) group vs. the intervention (ivf bolus + furosemide) group and will undergo point-of-care us (pocus) and bladder scanner evaluation of the bladder every 30 minutes until the bladder is determined to be full.

Eligibility criteria:
inclusion criteria: 1. females age 8-18yrs seen in the ed at ccmc who are undergoing a trans-abdominal pelvic ultrasound to assess for ovarian torsion 2. ability of patient (if 18yrs) or parent/legal guardian to sign a written informed consent exclusion criteria: 1. history of renal, genitourinary, or pelvic anomalies a. eg: chronic kidney disease, anuria, vesicoureteral reflux, ureteral obstruction, urologic reconstructive surgery, suprapubic or pelvic surgery, indwelling urethral catheter, oophorectomy, bicornate uterus 2. patients with multiple chronic illnesses or systemic neurologic abnormality a. eg: bronchopulmonary dysplasia, tracheostomy, gastrostomy tube dependence, cerebral palsy, severe developmental delay, mitochondrial disorder, congenital heart disease, cardiomyopathy, chronic kidney disease, diabetes 3. patients with known pregnancy 4. patients deemed to be critically ill a. mental status changes, signs of end organ damage, hypotension 5. contraindication to giving furosemide a. allergy to sulfonamide medications, severe dehydration, hypotension, underlying electrolyte abnormality, underlying renal disease 6. history of previous diuretic use within the past year 7. patients who self-report their bladder as being full at the time of enrollment

Keywords: pediatric point-of-care ultrasound bladder volume